Mike Hollan

Novartis filed paperwork in NJ revealing plans to layoff 322 workers in October of this year.

In today's Pharmaceutical Executive Daily, Vertex Pharmaceuticals announces a $10 billion acquisition of Crinetics Pharmaceuticals and its approved acromegaly therapy Palsonify, Catalent expands its partnership with Nanoscope Therapeutics to support potential commercialization of an optogenetic gene therapy for retinal degenerative diseases, and Cencora's Alina Chesnokova examines how the rise of specialty therapies is making cold chain logistics a front-line strategic priority.

Catalent will support Nanoscope’s commercialization of Nanoscope’s MCO-010.

The deal will bring Palsonify into Vertex’s pipeline.

The acquisition adds Myricx’s NMTi ADC delivery platform to Novartis’ pipeline.

The Troutman Pepper Locke senior associate discusses strategies for pharma and biotech companies to implement ahead of the July 31st tariff deadlines.

Troutman Pepper Locke senior associate Ryan Last explains when markets will start to significantly react to the upcoming pharma tariffs.

Ryan Last, senior associate at Troutman Pepper Locke explains how existing regulations and potential foreign countermeasures have a significant impact on reshoring efforts.

Troutman Pepper Locke senior associate Ryan Last explains how thin margins on certain product will impact the effectiveness of tariffs.

Ryan Last, senior associate at Troutman Pepper Locke, details the key steps that pharma companies must make before the July 31st deadline hits.

The decision was made based on the results of the BRUIN CLL-313 clinical study.

In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic triple-negative breast cancer — as both a monotherapy and in combination with Keytruda — marking the first new backbone therapy option for this aggressive disease in more than two decades, Novartis announces a $105 million collaborative agreement with Antares Therapeutics to jointly discover and develop first-in-class precision medicines in oncology and other serious diseases, with potential milestones totaling $1.8 billion, and Pharmaceutical Executive speaks with Kyle Smith, president and COO of Aprecia Pharmaceuticals, on the real-world benefits and persistent challenges of operating as a fully domestic manufacturer in an era of tariffs and supply chain pressure.

Novartis will fund Antares’ development of first-in-class precision medicines in cancer and other serious diseases.

Aprecia’s president and COO discusses the impact 3D printing technology is having on drug development, along with the benefits and challenges of being a company that is 100-percent US-based for its manufacturing.

In today's Pharmaceutical Executive Daily, Eli Lilly and Abbisko Therapeutics announce a new strategic research collaboration in which Abbisko will leverage its early-stage drug discovery platform to advance targets selected by Lilly, building on a prior partnership between the two companies, Pharmaceutical Executive speaks with Kyle Smith, president and COO of Aprecia Pharmaceuticals, on how the company's 3D printing technology enables real-time quality monitoring and rapid iteration to accelerate drug production, and life sciences industry advisor Partha Anbil examines the economics of the 340B Drug Pricing Program — including the forces driving its record $81.4 billion in 2024 purchases, the legal battles over manufacturer restrictions and rebate models, and what it all means strategically for pharmaceutical manufacturers in 2026.

Abbisko will utilize its drug development platform and R&D ecosystem to develop drug targets determined by Lilly.

Aprecia’s president and COO discusses the benefits of using 3D printing technology to quickly produce high quality drug tablet in a variety of dosages.

In today's Pharmaceutical Executive Daily, the FDA announces Operation TrialBlazer, a pilot program aimed at cutting early-stage clinical trial timelines by six to 12 months as the US looks to reclaim its footing in global clinical research, market access expert Manasi Salgaonkar explains why Class of Trade classification is becoming one of the hardest — and most consequential — problems in pharmaceutical commercial operations, and Pharmaceutical Executive speaks with Kyle Smith, president and COO of Aprecia Pharmaceuticals, on how DARPA's EQUIP-A-Pharma program is using federal investment to incentivize the reshoring of drug manufacturing to the United States.

Kyle Smith, president and COO of Aprecia, explains how the EQUIP-A-Pharma program is promoting the reshoring of pharma and biotech manufacturing.

In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding a suite of clinical-stage immunology assets to its portfolio, Insilico Medicine enters an AI-powered drug discovery collaboration with SK Biopharmaceuticals valued at up to $2.5 billion to advance neuroimmune treatments in the central nervous system, and Pharmaceutical Executive speaks with Kyle Smith, president and COO of Aprecia Pharmaceuticals, on the real-world benefits and persistent challenges of operating as a fully domestic manufacturer in an era of tariffs and supply chain pressure.

Insilico will use its AI platform for the drug development process, while SK handles the late-stage and commercialization processes.

The acquisition will bolster AbbVie’s pipeline, including the addition of monoclonal antibody treatment zumilokibart.

Aprecia’s president and COO Kyle Smith explains the challenges domestic manufacturers face when sourcing certain API and materials.

Kyle Smith, president and COO of Aprecia, discusses how additive manufacturing allows for the rapid development and manufacturing of a variety of dosage forms.

Novavax’s EVP of corporate affairs and head of its Sweden division discusses new vaccine technologies, such as its adjuvant matrix technology, are bringing new players into the space.

Silvia Taylor of Novavax explains how major biotechs like Eli Lilly and Sanofi are developing vaccine strategies for the coming years.

5 Prime Sciences CEO discusses how simply building a massive data set can cause more problems than it solves during clinical trials.

Polaryx’s chief medical officer discusses the regulatory environment for rare, pediatric treatments and how it’s directly impacting clinical trials.

Silvia Taylor of Novavax details how the company leverages its expertise in vaccine development to build partnerships across the industry.

The two executives discuss joining Persica Pharmaceuticals and how they’re driving the company forward with non-opioid pain medication.